(19)
(11) EP 1 225 168 B8

(12) CORRECTED NEW EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B2)

(48) Corrigendum issued on:
18.03.2015 Bulletin 2015/12

(45) Date of publication and mentionof the opposition decision:
21.01.2015 Bulletin 2015/04

(45) Mention of the grant of the patent:
14.01.2009 Bulletin 2009/03

(21) Application number: 02009255.7

(22) Date of filing: 06.09.1989
(51) International Patent Classification (IPC): 
A61K 31/5575(2006.01)
A61P 27/02(2006.01)
 A61P 27/06(2006.01)

(54)

Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension

Prostaglandin-F-2-alpha Derivat zur Behandlung von Glaukom und Augenhochdruck

Dérivé de prostaglandine-F-2-alpha pour le traitement du glaucome et de l'hypertension oculaire

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(30) Priority: 06.09.1988 SE 8803110
28.10.1988 SE 8803855

(43) Date of publication of application:
24.07.2002 Bulletin 2002/30

(62) Application number of the earlier application in accordance with Art. 76 EPC:
93109514.5 / 0569046
89850294.3 / 0364417

(73) Proprietor: Pfizer Health AB
191 90 Sollentuna (SE)

(72) Inventors:
  • Stjernschantz, Johan W.
    752 38 Uppsala (SE)
  • Resul, Bahram
    754 49 Uppsala (SE)

(74) Representative: Pfizer 
European Patent Department 23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14
75668 Paris Cedex 14 (FR)


(56) References cited: : 
EP-A- 0 093 380
CA-A1- 1 208 560
GB-A- 1 362 956
US-A- 3 962 312
 EP-A- 0 170 258
DE-A1- 2 234 709
GB-A- 1 364 125
US-A- 3 962 312
   
  • E. GRANSTRÖM: ' Prostaglandins', vol. 9, January 1975 pages 19 - 45
  • 'The Association for Research in Ophtalmology - Annual Spring Meeting', vol. 29, May 1988 page 325
  • ARVO Abstracts 1987